Related Experiment Video
Updated: Apr 5, 2026

Rapid Depletion of Renal Macrophages Using Human CD59/Intermedilysin Cell Ablation Tool
Published on: May 9, 2025
Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis
Melissa Inman1, Ginnie Prater1, Huma Fatima2
1Department of Medicine, Division of Nephrology , University of Alabama at Birmingham , Birmingham , AL , USA.
Abstract:
C3 glomerulopathy (C3G) is characterized by C3 deposits with minimal immunoglobulin deposition caused by alternative complement pathway dysregulation. Unfortunately, no therapeutic intervention has consistently improved outcomes for patients with C3G. Eculizumab, a monoclonal antibody to C5, is currently the only approved complement-specific agent with some efficacy in the treatment of C3 glomerulonephritis (C3GN). Here, we describe a patient with acute crescentic C3GN with no identified complement mutation or family history of renal disease who required dialysis for 6 months. Five months after initiation of eculizumab, she became dialysis independent, showing improvement is possible after adequate time on eculizumab.
More Related Videos
Related Concept Videos
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

